Literature DB >> 12213509

Effects of the selective dopamine D(1) antagonists NNC 01-0112 and SCH 39166 on latent inhibition in the rat.

Karen M Trimble1, Robert Bell, David J King.   

Abstract

Dopamine D(1) receptor blockade does not appear to be a prerequisite for antipsychotic activity since many clinically effective antipsychotics have little or no affinity for this receptor subtype. Clozapine, however, which has minimal liability for extrapyramidal symptoms, possesses affinities of similar order for D(1) and D(2) receptors. In earlier animal models used to predict antipsychotic effect, selective D(1) antagonists have shown effects similar to standard antipsychotics with preferential D(2) or mixed D(1)/D(2) antagonism. We investigated the effects of haloperidol (0.1 mg/kg) and two selective D(1) antagonists, NNC 01-0112 (0.05, 0.1 and 0.2 mg/kg) and SCH 39166 (0.02, 0.2 and 2.0 mg/kg), on latent inhibition (LI) in rats. LI is a behavioural paradigm in which repeated nonreinforced preexposure to a stimulus retards subsequent associations to that stimulus. Disrupted LI has been suggested as a model for the attentional deficits in schizophrenia. Using preexposure to a flashing light stimulus, which subsequently served as a conditioned stimulus for suppression of water licking, we demonstrated a clear LI effect with haloperidol but with neither of the two D(1) antagonists. Since selective D(1) antagonists are not clinically effective, these results add further credibility for the relevance of LI as an animal model of psychosis. Copyright 2002 Elsevier Science Inc.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12213509     DOI: 10.1016/s0031-9384(02)00814-4

Source DB:  PubMed          Journal:  Physiol Behav        ISSN: 0031-9384


  8 in total

1.  Involvement of D1 and D2 dopamine receptor in the retrieval processes in latent inhibition.

Authors:  E Diaz; J Medellín; N Sánchez; J P Vargas; J C López
Journal:  Psychopharmacology (Berl)       Date:  2015-09-08       Impact factor: 4.530

2.  Involvement of different types of dopamine receptors in the formation of latent inhibition of a conditioned passive avoidance reaction in rats.

Authors:  L V Loskutova; N V Kostyunina; N I Dubrovina
Journal:  Neurosci Behav Physiol       Date:  2010-05-21

Review 3.  The "two-headed" latent inhibition model of schizophrenia: modeling positive and negative symptoms and their treatment.

Authors:  Ina Weiner
Journal:  Psychopharmacology (Berl)       Date:  2003-02-25       Impact factor: 4.530

4.  Haloperidol and clozapine antagonise amphetamine-induced disruption of latent inhibition of conditioned taste aversion.

Authors:  Holger Russig; Aneta Kovacevic; Carol A Murphy; Joram Feldon
Journal:  Psychopharmacology (Berl)       Date:  2003-07-25       Impact factor: 4.530

5.  Enhanced latent inhibition in dopamine receptor-deficient mice is sex-specific for the D1 but not D2 receptor subtype: implications for antipsychotic drug action.

Authors:  Cecilie Bay-Richter; Colm M P O'Tuathaigh; Gerard O'Sullivan; David M Heery; John L Waddington; Paula M Moran
Journal:  Int J Neuropsychopharmacol       Date:  2008-11-17       Impact factor: 5.176

6.  Dopamine D1 receptor involvement in latent inhibition and overshadowing.

Authors:  Andrew J D Nelson; Karen E Thur; Helen J Cassaday
Journal:  Int J Neuropsychopharmacol       Date:  2011-12-16       Impact factor: 5.176

7.  A road less travelled by. A review lecture given to the Royal Irish Academy on the occasion of the Award of Merit and Silver Medal by the Consultative Committee for Pharmacology & Toxicology on 22 November 2001.

Authors:  David J King
Journal:  Ulster Med J       Date:  2003-11

8.  Potentiation of latent inhibition by haloperidol and clozapine is attenuated in Dopamine D2 receptor (Drd-2)-deficient mice: do antipsychotics influence learning to ignore irrelevant stimuli via both Drd-2 and non-Drd-2 mechanisms?

Authors:  Matthew J O'Callaghan; Cecilie Bay-Richter; Colm Mp O'Tuathaigh; David M Heery; John L Waddington; Paula M Moran
Journal:  J Psychopharmacol       Date:  2014-08-13       Impact factor: 4.153

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.